Monograph Details
|
|
Central Nervous System
> Mood disorders
|
|
REMERON |
| Manufacturer |
|
Schering Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Tetracyclic. |
| Generic Name |
|
Mirtazapine 15mg+, 30mg+, 45mg, tabs; +scored. |
| Also |
|
• REMERON SOLTAB
|
| Indications |
|
Depression. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 15mg once daily at bedtime; increase at intervals of at least 1–2 weeks. Usual range: 15–45mg daily. SolTab: Dissolve on tongue and swallow with or without water. |
| Contraindications |
|
During or within 14 days of MAOIs. |
| Precautions |
|
Hepatic or moderate to severe renal dysfunction. Diseases that affect metabolism or hemodynamic response. History of mania/hypomania. Seizure disorders. Suicidal ideation. History of MI. Angina. Ischemic stroke. Hypovolemia. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
See Contraindications. Possible serious/fatal reactions with MAOIs. Potentiation with alcohol, diazepam, other CNS depressants. Caution with drugs metabolized by and/or that inhibit CYP450. |
| Adverse Reactions |
|
Somnolence, increased appetite, weight gain, dizziness, nausea, dry mouth, constipation, asthenia, flu syndrome, edema, CNS effects; hypo- or hypertension, elevated cholesterol, triglycerides, or transaminases; agranulocytosis (rare). |
| How Supplied |
Tabs 15mg, 30mg—30, 100
45mg—30
SolTabs—30 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
